Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses

• Published in: Scientific reports Vol. 14; no. 1; pp. 7217 - 13
• Main Authors: Matsuura, Tomoka, Fukushima, Wakaba, Nakagama, Yu, Kido, Yasutoshi, Kase, Tetsuo, Kondo, Kyoko, Kaku, Natsuko, Matsumoto, Kazuhiro, Suita, Asae, Mukai, Emiko, Nitahara, Yuko, Konishi, Ayako, Kasamatsu, Ayane, Nakagama, Sachie, Nakagami-Yamaguchi, Etsuko, Ohfuji, Satoko, Kaneko, Yukihiro, Kaneko, Akira, Kakeya, Hiroshi, Hirota, Yoshio
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 27.03.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 2019-nCoV Vaccine mRNA-1273; 692/308/174; 692/499; Adult; Antibodies; Antibodies, Viral; Antibody response; BNT162 Vaccine; COVID-19; COVID-19 - prevention & control; COVID-19 Vaccines; Fever; Humanities and Social Sciences; Humans; Immunization; Immunosuppressive agents; Male; mRNA; multidisciplinary; Multivariate analysis; Prospective Studies; Regression analysis; RNA, Messenger; SARS-CoV-2; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Vaccination; Vaccines
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-57931-0

To evaluate the antibody response following the initial four doses of mRNA vaccines (BNT162b2 or mRNA-1273) in SARS-CoV-2-naïve healthy adults and investigate factors influencing antibody titer increases, this prospective cohort study was conducted in Japan from March 2021. The study included participants who received either the 1st and 2nd doses (n = 467), 3rd dose (n = 157), or 4th dose (n = 89). Blood samples were collected before and up to 6 months after each dose, and anti-receptor-binding domain antibody levels were measured. Multivariate analysis (usin multiple linear regression or linear mixed models) revealed several factors significantly associated with higher post-vaccination antibody levels, including mRNA-1273 vaccine (after the 1st and 2nd dose), male gender (after the 3rd and 4th doses), younger age (after the 1st and 2nd dose), non-smoking status (after the 2nd dose), non-use of immunosuppressive agents (after the 1st dose), higher pre-vaccination antibody titers (after the 2nd, 3rd, and 4th doses), and higher post-vaccination fever (after the 2nd and 4th doses). Furthermore, longer intervals since the last dose were significantly associated with higher antibody levels after the 3rd and 4th doses. These findings provide valuable insights for optimizing vaccination strategies.